Taking into account that only a subset of DLBCL patients benefited from ibrutinib, both genome-wide and targeted follow-up screens have discovered a multiprotein supercomplex, formed by MYD88, TLR9 and the BCR, that could be associated with ibrutinib responsiveness [68]. The gene discussed is MYD88; the disease is diffuse large B-cell lymphoma.